During the trial, half of the patients’ symptoms did not worsen for at least a year, and they were better able to have conversations, manage money or have hobbies than people who had not received the drug.
Dunanimab works by breaking down harmful amyloid plaques that build up in the brain and is the second drug shown to be effective.
Dr Richard Oakley, Director of Research at the Alzheimer Society, said: “After 20 years without new drugs for Alzheimer’s disease, we now have two potential new drugs in just twelve months. This could be the start of the end for Alzheimer’s disease.”
Dr Mark Bosch, from the Dementia Research Institute in the UK, added: “This clinical trial represents a real breakthrough, showing a significant slowing of cognitive decline. I believe this treatment has the potential to dramatically improve the lives of patients and their families today.
Read the Latest World News Today on The Eastern Herald.
